Urovant Is Severely Undervalued And Has A Major Catalyst Expected In 2020 [Seeking Alpha]
UROVANT SCIENCES LTD COMMON (UROV)
Last urovant sciences ltd common earnings: 2/13 04:15 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
Summary Urovant Sciences announced that the FDA has added its New Drug Application for vibegron, which is being used to treat patients with overactive bladder. Vibegron is also being explored in several other indications like men with overactive bladder who have BPH and patients with IBS-associated pain. Another product in development for symptoms of OAB includes URO-902, which is being explored in a Phase 2a study. Urovant Sciences had $131.9 million in cash as of December 31, 2019. If additional cash is needed, it can draw upon its loan agreement it made with the $212.5 million Sumitomo Loan Agreement. UROV announced that the FDA had accepted its New Drug Application (NDA) FDA Acceptance Brings About Catalyst Towards End Of Year The FDA had accepted Urovant's application for its drug vibegron for the treatment of patients with overactive bladder (OAB). Specifically, it is for patients with symptoms of , urgency and urinary frequency. The drug vibegron is a small molecule beta-3 agon
Show less
Read more
Impact Snapshot
Event Time:
UROV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UROV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UROV alerts
High impacting UROVANT SCIENCES LTD COMMON news events
Weekly update
A roundup of the hottest topics